{
    "clinical_study": {
        "@rank": "13551", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Giving drugs at the time of day that allows for the best drug\n      response may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor\n      cells.\n\n      PURPOSE: Randomized phase II trial to determine the best time to give irinotecan combined\n      with fluorouracil, leucovorin, and oxaliplatin in treating patients who have colorectal\n      cancer."
        }, 
        "brief_title": "Combination Chemotherapy in Treating Patients With Colorectal Cancer", 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the role of peak delivery time on the tolerability of irinotecan when\n           administered with chronomodulated fluorouracil, leucovorin calcium, and oxaliplatin as\n           first- or second-line therapy in patients with locoregional or metastatic colorectal\n           cancer.\n\n        -  Determine the antitumor activity of this regimen.\n\n      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to\n      participating center, WHO performance status (0-1 vs 2), and line of treatment (first vs\n      second). Patients are randomized to receive irinotecan at 1 of 6 different times of the day.\n\n      Patients receive irinotecan IV over 6 hours on day 1 and fluorouracil IV and leucovorin\n      calcium IV over 11 hours followed by oxaliplatin IV over 11 hours on days 2-5. Courses\n      repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 4 weeks until disease progression and then every 8 weeks\n      thereafter.\n\n      PROJECTED ACCRUAL: A maximum of 186 patients (31 per irinotecan administration time) will be\n      accrued for this study within 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed colorectal cancer\n\n          -  Unresectable metastatic or locoregional disease\n\n          -  At least 1 measurable lesion outside a previously irradiated area or an area treated\n             with physical devices (e.g., cryotherapy, laser, or thermoablation)\n\n          -  No prior enrollment in EORTC-05963\n\n          -  No symptomatic brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Over 18\n\n        Performance status:\n\n          -  WHO 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Neutrophil count greater than 2,000/mm^3\n\n          -  Platelet count at least 90,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2 times upper limit of normal (ULN)\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times ULN\n\n          -  No uncontrolled hypercalcemia\n\n        Cardiovascular:\n\n          -  No overt cardiac disease\n\n        Pulmonary:\n\n          -  No severe respiratory illness\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  Male patients must use effective barrier contraception during and for up to 6 months\n             after study\n\n          -  No baseline diarrhea greater than grade I (must have less than 4 stools per 24 hours)\n\n          -  No prior grade III or IV toxicity related to irinotecan\n\n          -  No sensory or motor neuropathy with functional impairment\n\n          -  No prior hypersensitivity to any study drug\n\n          -  No other primary tumor except basal cell skin cancer or carcinoma in situ of the\n             cervix\n\n          -  No uncontrolled infectious or chronic disease\n\n          -  No psychological, familial, sociological, or geographical condition that would\n             preclude study\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No concurrent prophylactic growth factor therapy\n\n        Chemotherapy:\n\n          -  At least 1 month since prior chemotherapy\n\n          -  No prior irinotecan, fluorouracil, leucovorin calcium, and oxaliplatin as combination\n             therapy\n\n          -  Other prior therapy containing irinotecan and/or oxaliplatin allowed\n\n          -  No more than 1 prior chemotherapy regimen for metastatic or locoregional disease\n\n          -  Adjuvant chemotherapy considered first-line therapy if tumor relapsed within 6 months\n             of completion of therapy\n\n        Endocrine therapy:\n\n          -  No concurrent corticosteroids except for emergencies\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  Palliative radiotherapy for bone lesion allowed except for disease progression\n\n        Surgery:\n\n          -  See Disease Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "June 6, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00039208", 
            "org_study_id": "EORTC-05011", 
            "secondary_id": "EORTC-05011"
        }, 
        "intervention": [
            {
                "intervention_name": "fluorouracil", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "irinotecan hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "leucovorin calcium", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "oxaliplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin", 
                "Irinotecan", 
                "Camptothecin", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "keyword": [
            "stage III colon cancer", 
            "stage IV colon cancer", 
            "stage III rectal cancer", 
            "stage IV rectal cancer", 
            "recurrent colon cancer", 
            "recurrent rectal cancer"
        ], 
        "lastchanged_date": "July 12, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-05011"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Charleroi", 
                        "country": "Belgium", 
                        "zip": "6000"
                    }, 
                    "name": "Centre Hospitalier Notre Dame - Reine Fabiola"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "B 4000"
                    }, 
                    "name": "Clinique Saint-Joseph"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "B-4000"
                    }, 
                    "name": "CHU Liege - Domaine Universitaire du Sart Tilman"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Namur", 
                        "country": "Belgium", 
                        "zip": "5000"
                    }, 
                    "name": "Clinique Sainte Elisabeth"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Verviers", 
                        "country": "Belgium", 
                        "zip": "B-4800"
                    }, 
                    "name": "Centre Hospitalier Peltzer-La Tourelle"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France", 
                        "zip": "63011"
                    }, 
                    "name": "Centre Jean Perrin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21079"
                    }, 
                    "name": "Centre de Lutte Contre le Cancer Georges-Francois Leclerc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France", 
                        "zip": "87042"
                    }, 
                    "name": "Centre Hospital Regional Universitaire de Limoges"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75475"
                    }, 
                    "name": "Hopital Saint-Louis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Cloud", 
                        "country": "France", 
                        "zip": "92211"
                    }, 
                    "name": "Centre Rene Huguenin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94804"
                    }, 
                    "name": "Hopital Paul Brousse"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bolzano", 
                        "country": "Italy", 
                        "zip": "39100"
                    }, 
                    "name": "Azienda Sanitaria di Bolzano"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chieti", 
                        "country": "Italy", 
                        "zip": "66100"
                    }, 
                    "name": "Universita G.D'Annunzio Di Chieti"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano (Milan)", 
                        "country": "Italy", 
                        "zip": "20153"
                    }, 
                    "name": "Ospedale San Carlo Borromeo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orbassano, (Torino)", 
                        "country": "Italy", 
                        "zip": "10043"
                    }, 
                    "name": "Azienda Ospedale S. Luigi at University of Torino"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy", 
                        "zip": "I-27100"
                    }, 
                    "name": "Fondazione Salvatore Maugeri"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "RIONERO in VULTURE", 
                        "country": "Italy", 
                        "zip": "I-58028"
                    }, 
                    "name": "Ospedale Oncologico Regionale"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy", 
                        "zip": "00161"
                    }, 
                    "name": "Istituto Regina Elena"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vigevano", 
                        "country": "Italy", 
                        "zip": "27029"
                    }, 
                    "name": "Istituto Clinico Beato Matteo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amadora", 
                        "country": "Portugal", 
                        "zip": "P-2700"
                    }, 
                    "name": "Hospital Fernando Fonseca"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France", 
                "Italy", 
                "Portugal"
            ]
        }, 
        "official_title": "Time Finding Study of Chronomodulated Irinotecan, 5 Fluorouracil, Leucovorin and Oxaliplatin as First or Second Chemotherapy Line Against Metastatic Colorectal Cancer", 
        "overall_official": {
            "affiliation": "Istituti Fisioterapici Ospitalieri - Roma", 
            "last_name": "Carlo Garufi, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Peak delivery time for CPT11 tolerability over  the first 3 courses of treatment in patients who started therapy", 
            "safety_issue": "Yes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00039208"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "citation": "Garufi C, Focan C, Tumolo S, et al.: Time finding study of chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L) and oxaliplatin (O) (chronoIFLO) against metastatic colorectal cancer: results from randomized EORTC 05011 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-2566, 2007."
        }, 
        "secondary_outcome": [
            {
                "measure": "Peak delivery time for CPT11 tolerability over  the first 3 courses of  treatment in patients who started therapy, excluding those who stopped prior to  course 3 for reasons other than toxicity", 
                "safety_issue": "Yes"
            }, 
            {
                "measure": "Peak delivery time for CPT11 activity over the first 3 courses", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Peak delivery time for CPT11 tolerability and efficacy over the first 6 courses", 
                "safety_issue": "Yes"
            }, 
            {
                "measure": "Severe toxic events assessed by CTC v2.0 after each course of chemotherapy", 
                "safety_issue": "Yes"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No"
            }
        ], 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2002", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }, 
    "geocoordinates": {
        "Azienda Ospedale S. Luigi at University of Torino": "45.007 7.537", 
        "Azienda Sanitaria di Bolzano": "46.497 11.358", 
        "CHU Liege - Domaine Universitaire du Sart Tilman": "50.633 5.58", 
        "Centre Hospital Regional Universitaire de Limoges": "45.834 1.261", 
        "Centre Hospitalier Notre Dame - Reine Fabiola": "50.411 4.445", 
        "Centre Hospitalier Peltzer-La Tourelle": "50.591 5.866", 
        "Centre Jean Perrin": "45.777 3.087", 
        "Centre Rene Huguenin": "48.848 2.208", 
        "Centre de Lutte Contre le Cancer Georges-Francois Leclerc": "47.322 5.041", 
        "Clinique Saint-Joseph": "50.633 5.58", 
        "Clinique Sainte Elisabeth": "50.465 4.868", 
        "Fondazione Salvatore Maugeri": "45.186 9.157", 
        "Hopital Paul Brousse": "48.793 2.359", 
        "Hopital Saint-Louis": "48.857 2.352", 
        "Hospital Fernando Fonseca": "38.762 -9.24", 
        "Istituto Clinico Beato Matteo": "45.317 8.859", 
        "Istituto Regina Elena": "41.891 12.494", 
        "Ospedale Oncologico Regionale": "40.927 15.671", 
        "Ospedale San Carlo Borromeo": "45.464 9.188", 
        "Universita G.D'Annunzio Di Chieti": "42.352 14.167"
    }
}